In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Anticoagulant-induced bleeding hazards



Expert's Introduction

Bleeding complications are best classified by use of the BARC (Bleeding Academic Research Consortium) classification. As severe (but not only) bleeding events have an impact on clinical outcome all health professionals (in the specialties concerned) should know the mechanism of action, effects and interactions of antithrombotic therapies. Major bleeding under vitamin K antagonists (VKA) is associated with 30% mortality, which increases to 50-70% if intracerebral haemorrhage takes place. A switch from VKA to the new (or direct) oral anticoagulants (NOACs or DOACs), if possible, has significantly reduced bleeding hazards including also ICH. An additional benefit for NOACs is the availability of antidotes, which exhibit a much faster action as the moderate effect of vitamin K or other compounds against VKA-induced bleedings.

Moreover, bleeding hazards increase with the indication for a combination of more antithrombotic agents (TAT) e.g. in triple antithrombotic therapy when an oral anticoagulant is combined with two antiplatelet agents but also with the prolongation of antithrombotic strategies.
Accordingly, recent data have shown a significant decrease in bleeding hazards when TAT is performed for maximal 1 month followed by a dual antithrombotic therapy (DAT, 1 OAC and 1 antiplatelet agent) or if a dual antithrombotic strategy is offered form the beginning in patients with atrial fibrillation after stent implantation.

Finally, the development and clinical investigation of new anticoagulants with a still lower bleeding event rate are ongoing.

 

huber-kurt-2013.jpgProf. Kurt Huber

Interventional cardiologist, Vienna, Austria

 

 

 

Cenko_Edina_2019.jpgResources have been selected by Dr. Edina Cenko

Young ACVC Member

Department of Experimental, Diagnostic and Specialty Medicine (DIMES) |University of Bologna, Italy

 

Intensive and Acute Cardiac Care Textbook - Online

escel-acca.jpgTopic 44: Fibrinolytic, antithrombotic, and antiplatelet drugs in acute coronary syndromes

 

Acute Cardiovascular Care Congress Resources

ESC365-2019-Visual-Grey.jpgA selection of resources from Acute Cardiovascular Care 2019:

 

Clinical Decision-Making Toolkit

ACCA-toolkit-2018-hands.jpg

  • Secondary Prevention after ACS- section: Antithrombotic treatment - P. 41
  • Drugs in Acute Cardiovascular Care - P. 121

 

Access the toolkit

 

ACVC Webinars

Scientific Papers from the EHJ-ACVC

ACVC Scientific Poster

  • Quality Indicators - Definition & Assessment

Access